

Abstract

The invention relates to peptides of the AT₁ receptor and their use for elimination of specifically binding, cell-physiologically active, pathological antibodies in preeclampsia and for their diagnostic proof.

Preferably, these are peptides with the sequence AFHYESQ, AVHYQSN, SHFYQTR, GYYFDTN or ENTNIT.